This week’s immunology update spotlights key developments, regulatory milestones, and the latest progress shaping the biopharma landscape. In Today’s Newsletter […] The post Immunology Today—November 12, 2025 appeared first on LucidQuest Ventures.

ESMO AI at a glance Get ready for ESMO AI and Digital Oncology 2025 with LucidQuest’s concise preview—spotlighting must-see sessions […] The post ESMO AI 2025 Preview: What to Watch in Oncology and AI appeared first on LucidQuest Ventures.

The FDA has removed the black box warning on menopause hormone therapy, expanding treatment options for women. In Canada, Elahere has been backed for coverage in treating platinum-resistant ovarian cancer, marking a major advancement. Gilead’s Trodelvy fails in a first-line breast cancer trial, though secondary results show promise. The WHO has launched an online course to improve breast cancer early detection. Meanwhile, Together Women’s Health expands in Tennessee, and Nestlé partners with universities to drive women’s health innovation.

This biweekly women’s health video brings you the latest breakthroughs in menopause care, ovarian cancer treatments, and exciting innovations in […] The post Women’s Health Video Recap—November 12, 2025 appeared first on LucidQuest Ventures.

Lucid Diligence Brief: myTomorrows $29 million funding to scale AI-enabled clinical-trial recruitment Professional audiences only. Not investment research or advice. […] The post Lucid Diligence Brief: myTomorrows $29 million funding to scale AI-enabled clinical-trial recruitment appeared first on LucidQuest Ventures.

This biweekly video recaps the latest breakthroughs in CNS therapeutics—from promising trials to cutting-edge technologies—spotlighting the trends shaping current research […] The post Neuroscience Video Recap—November 12, 2025 appeared first on LucidQuest Ventures.

This week’s neuroscience update spotlights key developments, regulatory milestones, and the latest progress shaping the biopharma landscape. In Today’s Newsletter […] The post Neuroscience Today — November 12, 2025 appeared first on LucidQuest Ventures.

Lucid Diligence Brief: INBRAIN and Microsoft partner on agentic AI for precision neurology and BCI Professional audiences only. Not investment […] The post Lucid Diligence Brief: INBRAIN and Microsoft partner on agentic AI for precision neurology and BCI appeared first on LucidQuest Ventures.

Pfizer has won a $10 billion bidding war for Metsera, beating Novo Nordisk, which withdrew due to antitrust concerns. Hanmi's Efpeglenatide Phase 3 results show promising weight loss and fewer side effects compared to competitors. Eli Lilly is moving forward with its oral GLP-1 candidate, orforglipron, while its tirzepatide continues to dominate sales, surpassing Merck’s Keytruda. Meanwhile, Wave Life Sciences reports significant progress with its RNAi therapy for obesity. Korea’s MFDS is reviewing potential misuse concerns surrounding obesity drugs like Wegovy.

Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional audiences only. Not investment research or advice. UK readers: for persons under […] The post Lucid Diligence Brief: Galecto acquires Damora Therapeutics appeared first on LucidQuest Ventures.

This biweekly obesity video recap reviews major moves shaping the obesity and metabolic landscape—from strategic deals and late-stage data to […] The post Obesity Video Recap—November 11, 2025 appeared first on LucidQuest Ventures.

This week in endocrinology: fresh clinical readouts, market-moving industry moves, and updates from top biopharma players. In Today’s Newsletter Dive […] The post Endocrinology Today—November 11, 2025 appeared first on LucidQuest Ventures.

Track this week’s obesity headlines: Obesity Week 2025 highlights, industry activity, clinical milestones, and biopharma breakthroughs. In this Newsletter Dive […] The post Obesity Today—November 11, 2025 appeared first on LucidQuest Ventures.

Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery Professional audiences only. Not investment research or advice. UK readers: […] The post Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery appeared first on LucidQuest Ventures.

Oncology Update spotlights major global advances, led by the European Commission’s approval of Keytruda for resectable PD-L1–positive head and neck cancer after KEYNOTE-689 showed a 30 percent event-free survival improvement. Cellectar gains FDA Rare Pediatric Disease Designation for iopofosine I-131 in pediatric glioma, while A2 Biotherapeutics reports the first complete CAR T response in NSCLC. Additional highlights include Akeso’s fourth Breakthrough Therapy Designation for ivonescimab in triple-negative breast cancer, Canada’s approval of Enhertu and Elahere’s reimbursement support, and FDA-backed Phase 3 paths for NDV-01 in bladder cancer.

This week’s Hematology update spotlights  fresh breakthroughs, regulatory milestones, and trends redefining patient care. In Today’s Newsletter Dive deeper 🧬 […] The post Hematology Today—November 10, 2025 appeared first on LucidQuest Ventures.

🎯 Watch Our Video Summary Capturing Hematology News from the Last Two Weeks Dive deeper 🗓️ Explore weekly details and […] The post Oncology Video Recap—November 10, 2025 appeared first on LucidQuest Ventures.

This week’s Oncology update spotlights key developments, regulatory milestones, and the latest progress shaping the biopharma landscape. In this newsletter […] The post Oncology Today—November 10, 2025 appeared first on LucidQuest Ventures.

This week’s AI in Healthcare and Digital Health brief distills AI-driven developments in biopharma, digital health, clinical research, and policy […] The post AI in Healthcare and Digital Health Today—November 10, 2025 appeared first on LucidQuest Ventures.

Lucid Diligence Brief: SanegeneBio and Lilly RNAi collaboration in metabolic diseases Professional audiences only. Not investment research or advice. UK […] The post Lucid Diligence Brief: SanegeneBio and Lilly RNAi collaboration in metabolic diseases appeared first on LucidQuest Ventures.

Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding Professional audiences only. Not investment research or advice. UK readers: for persons […] The post Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding appeared first on LucidQuest Ventures.

Lucid Diligence Brief: Lumonus A$25M Series B Professional audiences only. Not investment research or advice. UK readers: for persons under […] The post Lucid Diligence Brief: Lumonus A$25M Series B appeared first on LucidQuest Ventures.

AHA at a glance Get ready for AHA 2025 with LucidQuest’s concise preview. We spotlight must-see sessions and emerging themes […] The post AHA 2025 Preview: Key Cardiovascular and AI Highlights to Watch appeared first on LucidQuest Ventures.

Recent findings reveal viral infections like flu, COVID-19, and shingles significantly raise cardiovascular risk, reinforcing the value of vaccination. A study shows a single 15-minute walk offers stronger heart protection than multiple short strolls. McGill engineers unveiled a 2.7 mm bioprinter to repair vocal cords, while Warwick scientists discovered a powerful new antibiotic active against MRSA and VRE. Duke-NUS mapped the developing brain to improve Parkinson’s therapies, and new data suggest many breast cancer patients may safely skip post-mastectomy radiotherapy.

This week’s respiratory update spotlights key developments, regulatory milestones, and the latest progress shaping the biopharma landscape. In Today’s Newsletter […] The post Respiratory Today—November 7, 2025 appeared first on LucidQuest Ventures.